REGγ promotes mantle cell lymphoma cell apoptosis by downregulating NF-κB signaling. 2023

Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
Second Department of Oncology, Guangdong Second Provincial General Hospital, School of Medicine, Jinan University, Guangzhou, China.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL). REGγ is important for tumor occurrence and development, but understanding of the specific role of REGγ in MCL is lacking. We aimed to identify REGγ effects on the proliferation and apoptosis of MCL cells and clarify the underlying mechanisms. JEKO-1 cells stably transfected with a doxycycline-inducible Tet-On system expressed high levels of REGγ. JEKO-1 cells stably expressing shRNA-REGγ to reduce REGγ levels were constructed. Cell proliferation, apoptosis, and p-NF-κB, NF-κB, IkB, REGγ, p-STAT3, STAT3, and PSMB5 levels in transfected cells and in transfected cells treated with Stattic, that is a nonpeptidic small molecule exhibited to selectively inhibit signal transducer and activator of transcription factor 3 through blocking the function of its SH2 domain, were analyzed using western blotting. The proliferation of JEKO-1 cells was inhibited, and apoptosis was enhanced by increased expression of REGγ (P<0.01). REGγ inhibited MCL cell proliferation in a mouse tumor xenograft model by promoting apoptosis, increased the expression of the three IκB subunits and inhibited NF-κB signaling. Overexpressed REGγ inhibited STAT3 and downregulated PSMB5 expression in MCL cells. Stattic downregulated PSMB5 and nuclear factor-kappa B (NF-κB) expressions and upregulated IκBε expression in JEKO-1 cells. We found that REGγ regulated p-STAT3 expression by accelerating its half-life and downregulated the NF-κB signaling pathway to promote MCL cell apoptosis by negatively regulating STAT3-mediated PSMB5 expression and subsequently upregulating IκB expression.

UI MeSH Term Description Entries

Related Publications

Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
July 2017, Oncotarget,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
June 2018, Hematology (Amsterdam, Netherlands),
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
June 2018, Journal of hematology & oncology,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
January 2015, PloS one,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
February 2022, Cancer cell international,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
July 2016, Blood,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
August 2010, Leukemia,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
February 2017, Oncotarget,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
February 2011, Translational oncology,
Xin-Xin Zeng, and Wan-Wei Guo, and Ju Shen, and Yu-Ying Jiang, and Shuang Liu, and Xu-Hui Zhang
November 2016, Cancer research,
Copied contents to your clipboard!